Corbus Pharmaceuticals Holdings, Inc. (CRBP): Price and Financial Metrics


Corbus Pharmaceuticals Holdings, Inc. (CRBP): $1.67

0.28 (+20.14%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add CRBP to Watchlist
Sign Up

Industry: Biotech


Ranked

of 493

in industry

CRBP POWR Grades


  • Growth is the dimension where CRBP ranks best; there it ranks ahead of 79.09% of US stocks.
  • CRBP's strongest trending metric is Quality; it's been moving up over the last 206 days.
  • CRBP's current lowest rank is in the Stability metric (where it is better than 5.71% of US stocks).

CRBP Stock Summary

  • As for revenue growth, note that CRBP's revenue has grown -89.07% over the past 12 months; that beats the revenue growth of only 1.69% of US companies in our set.
  • In terms of volatility of its share price, CRBP is more volatile than 99.01% of stocks we're observing.
  • Shareholder yield, a measure of how much is returned to shareholders via dividends and share repurchases, for CRBP comes in at -92.66% -- higher than that of only 2.95% of stocks in our set.
  • Stocks with similar financial metrics, market capitalization, and price volatility to Corbus Pharmaceuticals Holdings Inc are ARCT, MTEM, BBI, JNCE, and PIRS.
  • Visit CRBP's SEC page to see the company's official filings. To visit the company's web site, go to www.corbuspharma.com.

CRBP Price Target

For more insight on analysts targets of CRBP, see our CRBP price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $1.88 Average Broker Recommendation 1.92 (Hold)

CRBP Stock Price Chart Interactive Chart >

Price chart for CRBP

CRBP Price/Volume Stats

Current price $1.67 52-week high $9.78
Prev. close $1.39 52-week low $0.91
Day low $1.36 Volume 6,501,100
Day high $1.75 Avg. volume 10,802,281
50-day MA $1.88 Dividend yield N/A
200-day MA $2.54 Market Cap 208.81M

Corbus Pharmaceuticals Holdings, Inc. (CRBP) Company Bio


Corbus Pharmaceuticals Holdings, Inc., a clinical stage pharmaceutical company, focuses on the development and commercialization of novel therapeutics to treat inflammatory and fibrotic diseases. The company is based in Norwood, Massachusetts.


CRBP Latest News Stream


Event/Time News Detail
Loading, please wait...

CRBP Latest Social Stream


Loading social stream, please wait...

View Full CRBP Social Stream

Latest CRBP News From Around the Web

Below are the latest news stories about Corbus Pharmaceuticals Holdings Inc that investors may wish to consider to help them evaluate CRBP as an investment opportunity.

Corbus Pharmaceuticals to Present at Three Upcoming Investor Conferences

Norwood, MA, May 11, 2021 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a clinical-stage drug development company pioneering transformative medicines that target the endocannabinoid system, today announced that Yuval Cohen, Ph.D., Chief Executive Officer of Corbus, will be presenting at three upcoming virtual investor conferences. The following are the details for the conferences: 2021 RBC Capital Markets Global Healthcare Conference Event: Fireside Chat Discussion and Q&ADate and Time: Tuesday, May 18, 2021, at 3:40pm EST Oppenheimer Rare & Orphan Disease Summit Event: Fireside Chat Discussion and Q&ADate and Time: Friday, May 21, 2021, at 9:55am EST Jefferies Virtual Global Healthcare Conference Event: Fireside Chat Discussion an...

Yahoo | May 11, 2021

Corbus Pharmaceuticals (CRBP) May Report Negative Earnings: Know the Trend Ahead of Q1 Release

Corbus Pharmaceuticals (CRBP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Yahoo | May 3, 2021

Corbus: Assessing If Lenabasum Can Finally Break Through

Photo by Andrew Brookes/Cultura via Getty ImagesWe wrote about Corbus Pharmaceuticals (NASDAQ:CRBP) back in January and stated that the recent unsuccessful Lenabasum phase 3 and phase 2 trials would not end up being a death sentence for the firm. Expectations were very high before the result which meant a soft...

Individual Trader on Seeking Alpha | April 15, 2021

Corbus Pharmaceuticals Reports Last Subject Visit in DETERMINE Phase 3 Study of Lenabasum for Treatment of Dermatomyositis

Topline data on schedule for Q2 2021Dermatomyositis is a rare and life-threatening autoimmune disease characterized by skin and muscle inflammation, and affects ~80,000 people in North America, EU, and JapanThere is a significant need for safer and more effective treatments in dermatomyositis because of limitations of current treatment options Norwood, MA, March 30, 2021 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a clinical-stage drug development company pioneering transformative medicines that target the endocannabinoid system, today announced that the last subject completed the final visit in the double-blind, placebo-controlled part of the Company’s Phase 3 DETERMINE study of lenabasum for the treatment of dermatomyositis. Th...

Yahoo | March 30, 2021

Cannabis Stock Gainers And Losers From March 19, 2021

GAINERS: SugarBud Craft Growers (PINK: RLLRF ) shares closed up 26.19% at $0.05 Cipher Pharms Inc (PINK: CPHRF ) shares closed up 17.11% at $0.89 Chemesis International (PINK: CADMF ) shares closed up 16.82% at $0.71 CANADA HOUSE WELLNESS GRP (OTC: SARSF ) shares closed up 15.62% at $0.04 GTEC Holdings (OTCQB: GGTTF ) shares closed up 14.2% at $0.72 Zynerba Pharmaceuticals (NASDAQ: ZYNE ) shares closed up 9.94% at $5.31 Corbus Pharmaceuticals (NASDAQ: CRBP ) shares closed up 8.8% at $2.35 Tetra Bio Pharma (OTCQB: TBPMF ) shares closed up 8.02% at $0.16 GrowGeneration (NASDAQ: GRWG ) shares closed up 7.94% at $54.78 High Tide (OTCQB: HITIF ) shares closed up 6.27% … Full story available on Benzinga.com

Benzinga | March 19, 2021

Read More 'CRBP' Stories Here

CRBP Price Returns

1-mo -5.11%
3-mo -44.15%
6-mo 36.89%
1-year -75.67%
3-year -73.28%
5-year -28.63%
YTD 33.60%
2020 -77.11%
2019 -6.51%
2018 -17.75%
2017 -15.98%
2016 412.12%

Continue Researching CRBP

Here are a few links from around the web to help you further your research on Corbus Pharmaceuticals Holdings Inc's stock as an investment opportunity:

Corbus Pharmaceuticals Holdings Inc (CRBP) Stock Price | Nasdaq
Corbus Pharmaceuticals Holdings Inc (CRBP) Stock Quote, History and News - Yahoo Finance
Corbus Pharmaceuticals Holdings Inc (CRBP) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.952 seconds.